SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardiop...

Full description

Bibliographic Details
Main Authors: Roko Skrabic, Marko Kumric, Josip Vrdoljak, Doris Rusic, Ivna Skrabic, Marino Vilovic, Dinko Martinovic, Vid Duplancic, Tina Ticinovic Kurir, Josko Bozic
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Biomedicines
Subjects:
SGLT2 inhibitor
chronic kidney disease
diabetes mellitus
Online Access:https://www.mdpi.com/2227-9059/10/10/2458

Internet

https://www.mdpi.com/2227-9059/10/10/2458

Similar Items